

# Mafalda Oliveira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1989630/publications.pdf>

Version: 2024-02-01

123  
papers

6,136  
citations

136950

32  
h-index

76900

74  
g-index

126  
all docs

126  
docs citations

126  
times ranked

6973  
citing authors

#	ARTICLE	IF	CITATIONS
1	High FGFR1 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 137-149.	7.0	12
2	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 565-576.	2.5	32
3	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. <i>Cancer Research</i> , 2022, 82, P2-14-13-P2-14-13.	0.9	1
4	Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102362.	7.7	33
5	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 993-1003.	7.0	21
6	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. <i>Cancer Research</i> , 2022, 82, 1646-1657.	0.9	40
7	Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 254-255.	1.6	1
8	Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2). , 2021, , .		1
9	Abstract OT-09-08: Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer. , 2021, , .		1
10	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
11	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021, 5, 23.	5.4	26
12	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 1581-1591.	6.4	12
13	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	27.0	601
14	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 449-458.	2.5	2
15	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638482.	2.8	16
16	RECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 2557-2557.	1.6	0
17	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	3.7	31
18	Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 2927.	3.7	54

#	ARTICLE	IF	CITATIONS
19	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
20	Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 377-386.	2.5	38
21	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.1	7
22	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	7.0	14
23	Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1148-1156.	1.2	146
24	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021, 11, 744112.	2.8	3
25	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	5.2	9
26	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	6.3	97
27	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 33-43.	10.7	105
28	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
29	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	7.0	70
30	Metabolic Imaging Detects Resistance to PI3K $\alpha$ Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 516-533.e9.	16.8	38
31	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With $\geq 2$ HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
32	10 Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with $\geq 2$ HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial. <i>Annals of Oncology</i> , 2020, 31, S15.	1.2	9
33	Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). <i>Breast</i> , 2020, 54, 286-292.	2.2	4
34	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
35	Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 731-741.	2.4	6
36	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5820-5829.	7.0	68

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1012-1024.	3.0	11
38	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , 2020, 4, 505-513.	3.0	10
39	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
40	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020, 16, 1801-1813.	2.4	8
41	Tackling the Biological Diversity in Early Triple-Negative Breast Cancer. <i>Breast Care</i> , 2020, 15, 205-207.	1.4	2
42	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	12.8	67
43	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	7.0	54
44	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3720-3731.	7.0	21
45	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2 <sup>+</sup> Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	7.0	11
46	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1005-1005.	1.6	8
47	A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1024-1024.	1.6	25
48	CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1111-TPS1111.	1.6	2
49	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	10.7	76
50	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	2.5	4
51	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	7.0	17
52	FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, 1289-1297.	1.2	97
53	Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. <i>Annals of Oncology</i> , 2019, 30, 945-952.	1.2	103
54	BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. <i>Annals of Oncology</i> , 2019, 30, 774-780.	1.2	57

#	ARTICLE	IF	CITATIONS
55	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. <i>Genome Medicine</i> , 2019, 11, 1.	8.2	84
56	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45.	2.4	14
57	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019, 17, 8.	5.5	28
58	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1002-1002.	1.6	71
59	Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1075-1075.	1.6	2
60	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018, 29, 170-177.	1.2	84
61	Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study). <i>Annals of Oncology</i> , 2018, 29, viii90.	1.2	0
62	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	1.8	36
63	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387.	7.0	49
64	Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX). , 2018, , .		1
65	Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC). , 2018, , .		4
66	Abstract CT046: A phase I basket study of the PI3K inhibitor tselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors. <i>Cancer Research</i> , 2018, 78, CT046-CT046.	0.9	4
67	Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1008-1008.	1.6	24
68	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 509-509.	1.6	10
69	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1101-TPS1101.	1.6	5
70	IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1117-TPS1117.	1.6	16
71	Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1073.	1.6	7
72	Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2018, 78, 2964-2964.	0.9	1

#	ARTICLE	IF	CITATIONS
73	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 545-554.	10.7	250
74	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1360-1372.	10.7	377
75	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, 23.	5.2	8
76	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 102-113.	9.4	136
77	Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort. <i>Breast</i> , 2017, 36, S46-S47.	2.2	0
78	Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC). <i>Annals of Oncology</i> , 2017, 28, v68.	1.2	0
79	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). <i>Annals of Oncology</i> , 2017, 28, v605.	1.2	103
80	LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1009-1009.	1.6	3
81	A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1114-TPS1114.	1.6	3
82	CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS594-TPS594.	1.6	0
83	Abstract 150: Identification of determinants of sensitivity to AKT inhibition using breast cancer (BC) patient-derived tumor xenografts (PDX). , 2017, , .		0
84	Abstract 3129: Patient-derived tumor xenografts (PDXs) recapitulate the antitumor activity of novel therapies in metastatic breast cancer (MBC) patients (pts). , 2017, , .		0
85	Phase 2 Study of Trabectedin in Patients With Hormone Receptor—Positive, HER-2—Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. <i>Clinical Breast Cancer</i> , 2016, 16, 364-371.	2.4	5
86	Web Accessibility for Elderly. , 2016, , .		1
87	POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2520-2520.	1.6	6
88	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2572-2572.	1.6	2
89	A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 520-520.	1.6	21
90	Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 537-537.	1.6	2



#	ARTICLE	IF	CITATIONS
91	LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS613-TPS613.	1.6	3
92	Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.. Journal of Clinical Oncology, 2016, 34, TPS11621-TPS11621.	1.6	0
93	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 528-528.	1.6	3
94	FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS1105-TPS1105.	1.6	0
95	Abstract 2825: Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX). , 2016, , .		0
96	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	12.8	605
97	SEOM clinical guidelines in metastatic breast cancer 2015. Clinical and Translational Oncology, 2015, 17, 946-955.	2.4	25
98	P200 Neoadjuvant therapy in HER2+ breast cancer: Opti-HER Heart run-in phase safety data (SOLTI-1002). Breast, 2015, 24, S93.	2.2	1
99	Abstract CT331: "BEECH", a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s. , 2015, , .		2
100	Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer. Cancer Research, 2015, 75, PD5-2-PD5-2.	0.9	11
101	LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, TPS1111-TPS1111.	1.6	3
102	FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, TPS1112-TPS1112.	1.6	1
103	PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, TPS642-TPS642.	1.6	1
104	Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer. , 2015, , .		0
105	Abstract OT1-1-16: A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC). , 2015, , .		0
106	Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors. Cancer Research, 2015, 75, 930-930.	0.9	2
107	Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies. , 2015, , .		0
108	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Annals of Oncology, 2014, 25, 1729-1735.	1.2	308

#	ARTICLE	IF	CITATIONS
109	Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. <i>Breast</i> , 2013, 22, 19-23.	2.2	27
110	Management of the axilla in early breast cancer patients in the genomic era. <i>Annals of Oncology</i> , 2013, 24, 1163-1170.	1.2	9
111	PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS665-TPS665.	1.6	0
112	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2013, 31, 547-547.	1.6	1
113	882 Evaluation of Synergy Between Novel PI3K-pathway Inhibitors and Microtubule-targeting Agents in HER2-negative Breast Cancer. <i>European Journal of Cancer</i> , 2012, 48, S213.	2.8	0
114	Intrathecal Trastuzumab in the Treatment of Leptomeningeal Metastases from Her2-Positive Cancer. <i>Annals of Oncology</i> , 2012, 23, ix141.	1.2	0
115	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 509-509.	1.6	3
116	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS652-TPS652.	1.6	1
117	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 566-566.	1.6	0
118	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10511-10511.	1.6	0
119	Abstract P6-13-03: Symptomatic bone marrow involvement (BMinv) in breast cancer (BC): Clinical presentation, treatment and prognosis according to BC subtype and Zoledronic acid (ZA) use. A single institution review. , 2012, , .		0
120	Complete response in HER2+leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 841-844.	2.5	59
121	P5-13-01: Survival Outcome with Bevacizumab: Activation of the Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA Mutations or PTEN Loss Makes a Difference.. , 2011, , .		1
122	Sudden death during adjuvant trastuzumab therapy of breast cancer. <i>Annals of Oncology</i> , 2010, 21, 901.	1.2	6
123	Late toxicity and quality of life in oral cavity and oropharyngeal cancer survivors treated with chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, 9092-9092.	1.6	0